TY - JOUR
T1 - On Optimal Designs for Clinical Trials
T2 - An Updated Review
AU - Sverdlov, Oleksandr
AU - Ryeznik, Yevgen
AU - Wong, Weng Kee
N1 - Funding Information:
The authors would like to thank three anonymous reviewers for their constructive comments that have helped improve the original version of the manuscript. Wong was partially supported by a grant from the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R01GM107639. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Funding Information:
The authors would like to thank three anonymous reviewers for their constructive comments that have helped improve the original version of the manuscript. Wong was partially supported by a grant from the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R01GM107639. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2019, Grace Scientific Publishing.
PY - 2020/3/1
Y1 - 2020/3/1
N2 - Optimization of clinical trial designs can help investigators achieve higher quality results for the given resource constraints. The present paper gives an overview of optimal designs for various important problems that arise in different stages of clinical drug development, including phase I dose–toxicity studies; phase I/II studies that consider early efficacy and toxicity outcomes simultaneously; phase II dose–response studies driven by multiple comparisons (MCP), modeling techniques (Mod), or their combination (MCP–Mod); phase III randomized controlled multi-arm multi-objective clinical trials to test difference among several treatment groups; and population pharmacokinetics–pharmacodynamics experiments. We find that modern literature is very rich with optimal design methodologies that can be utilized by clinical researchers to improve efficiency of drug development.
AB - Optimization of clinical trial designs can help investigators achieve higher quality results for the given resource constraints. The present paper gives an overview of optimal designs for various important problems that arise in different stages of clinical drug development, including phase I dose–toxicity studies; phase I/II studies that consider early efficacy and toxicity outcomes simultaneously; phase II dose–response studies driven by multiple comparisons (MCP), modeling techniques (Mod), or their combination (MCP–Mod); phase III randomized controlled multi-arm multi-objective clinical trials to test difference among several treatment groups; and population pharmacokinetics–pharmacodynamics experiments. We find that modern literature is very rich with optimal design methodologies that can be utilized by clinical researchers to improve efficiency of drug development.
UR - https://www.scopus.com/pages/publications/85081415089
UR - https://www.scopus.com/pages/publications/85081415089#tab=citedBy
U2 - 10.1007/s42519-019-0073-4
DO - 10.1007/s42519-019-0073-4
M3 - Article
AN - SCOPUS:85081415089
SN - 1559-8608
VL - 14
JO - Journal of Statistical Theory and Practice
JF - Journal of Statistical Theory and Practice
IS - 1
M1 - 10
ER -